Industry News
Stay in the know with ASTRO’s Corporate Members!
Staying up to date with ASTRO's Corporate Members has never been easier! Now ASTRO members can find press releases and announcements surrounding industry involved with radiation oncology on ASTRO’s new industry webpage.
Novocure has announced positive topline results from the pivotal Phase 3 PANOVA-3 clinical trial
Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
October 30, 2024
Gilead Oncology invites you to an upcoming webinar “A New Lens on Lung Cancer: Infusing Lung Cancer Conversations with HIV Learnings.”
In recognition of Lung Cancer Awareness Month, this event will bring together patients, caregivers, and other experts in the field to discuss fostering a more empathetic and informed approach to lung cancer. The webinar will be hosted by Gilead in partnership with Gryt Health and is scheduled for Thursday, November 21, at 12:00 p.m. Eastern time.
Here’s what you can expect:
Webinar Title: A New Lens on Lung Cancer: Infusing Lung Cancer Conversations with HIV Learnings
Date: Thursday, November 21
Time: 12:00 p.m. Eastern time | 9:00 a.m. Pacific time
Description: Shame and blame linked to lung cancer can lead to depression, discrimination, reduced quality of life and delays in screening, diagnosis and care. Gilead and Gryt Health are calling on all of us to help change the dialogue. During this webinar, you will hear from a panel of speakers, including patients, caregivers and advocates. The conversation will explore the critical and persistent challenges the lung cancer community faces and how we can apply lessons from the HIV community to foster a more empathetic and informed approach to this complex illness.
To secure your spot for this webinar, please register here.
October 30, 2024
Novocure Reports Third Quarter 2024 Financial Results
Novocure announced that the U.S. FDA has granted Breakthrough Device designation for the use of TTFields therapy for brain metastases from non-small cell lung cancer.
September 26, 2024
RICOH 3-D for Healthcare and Kallisio partner to enhance radiation oncology care with Stentra™ oral stent
EXTON, PA, September 26, 2024 Ricoh USA, Inc. and Kallisio today announced a strategic partnership to manufacture and distribute Stentra™, a 510(k)-cleared, patient-specific oral stent designed to improve radiation therapy for head and neck cancer (HNC) patients. Developed using technology exclusively licensed from MD Anderson Cancer Center, Stentra™ is engineered to protect healthy tissue by precisely displacing and immobilizing sensitive areas during treatment, allowing for more targeted and effective radiation delivery. This innovation is crucial in minimizing side effects and enhancing overall treatment outcomes. Read full press release.
